Ankaferd BloodStopper® (ABS) is an herbal extract which has been used historically as a haemostatic agent in traditional Turkish medicine. ABS comprises of standardized mixture of herbs Thymus vulgaris, Glycyrrhiza glabra, Vitis vinifera, Alpinia officinarum and Urtica dioica. Basic effect mechanism of ABS is the formation of an encapsulated protein web which represents the focus points for the vital erythrocyte masses. The haemostatic effects have been demonstrated by in vitro and in vivo studies. The usage of ABS as a hemostatic agent in external hemorrhages and in dental treatment in humans constitutes the first hints on ABS's safety and efficacy in humans. A phase I randomized, double-blinded, cross-over, placebo controlled clinical study in healthy volunteers indicated the safety of ABS. The aim of this report is to depict hemostatic effects of ABS in critical bleedings due to hemorrhagic diathesis, refractory to conventional measures in distinct clinical settings.
INTRODUCTION
Ankaferd Blood Stopper (ABS) comprises a standardized mixture of the plants Thymus vulgaris, Glycyrrhiza glabra, Vitis vinifera, Alpinia officinarum and Urtica dioica. 1 Each one of these herbs is effective over endothelium, blood cells, angiogenesis, cell proliferation, vascular dynamics, and mediators. 2, 3 The herbal extract has been used historically as a haemostatic agent in traditional Turkish medicine. 4, 5 The basic mechanism of action for ABS is the formation of an encapsulated protein network that provides focal points for vital erythrocyte aggregation.
2,3 ABS-induced protein network formation with blood cells particularly erythrocytes covers the primary and secondary haemostatic system without disturbing individual coagulation factors. This unique mechanism provides advantage to ABS, compared with other agents that have haemostatic effect. Exposure to ABS in a certain area provides physiological haemostatic process together with tissue oxygenisation, without calling out any individual coagulation factor. 2, 3, 6, 7 Göker and coworkers suggested that ABS causes an encapsulated protein web formation which will induce erythrocyte aggregation, affecting the fibrinogenerythrocyte agglutination relationship. 3 There are distinct important molecular components of the Ankaferd-induced hemostatic network. Vital erythroid aggregation takes place with the spectrin ankrin and actin proteins on the membrane of red blood cells. Essential erythroid proteins (Ankrin recurrent and FYVE bundle containing protein 1, Spectrin alpha, Actin-depolimerisation factor, Actin-depolimerizing factor, LIM bundle and actine binding subunit 1 isoform a, LIM bundle and actine binding subunit 1 isoform b, NADP-dependent malic enzyme, NADH dehydrogenase (Ubiquinone) 1 alpha subcomplex, Mitochondrial NADP (+) dependent malic enzyme 3, Ribulose bisphosphatecarbocsilase large chain, Maturase K) and the required ATP bioenergy (ATP synthase, ATP synthase beta subunit, ATP synthase alpha subunit, ATP-binding protein C12, TP synthase H+ transporter protein, ADF, Alpha-1,2-glycosyltransferase ALG10-A) are included in the protein library of Ankaferd. Ankaferd also upregulates GATA/FOG transcription system affecting erythroid functions and urotensin II. 1, 8 ABS is a hemostatic agent that can be used effectively in the clinical practices, to control external bleedings, dental and periodontal hemorrhage, skin bleedings and/or superficial mucosal blood leakages. [9] [10] [11] [12] The haemostatic effects have been demonstrated by in vitro and in vivo studies. [13] [14] [15] [16] [17] [18] [19] The usage of ABS as a hemostatic agent in external hemorrhages and in dental treatment in humans constitutes the first hints on ABS's safety and efficacy in humans. 10 A phase I randomized, double-blinded, cross-over, placebo controlled clinical study in healthy volunteers indicated the safety of ABS. The aim of this report is to depict hemostatic effects of ABS in critical bleedings due to hemorrhagic diathesis, refractory to conventional measures in distinct clinical settings.
CLINICAL STATES OF HEMORRHAGIC DIATHESIS

Topical ABS application in treatment of epistaxis refractory to thrombocyte transfusion during aplasic period after allogeneic stem cell transplantation in aplastic anemia
Allogeneic stem cell transplantation (AlloSCT) from a full compatible sibling is performed in a 20 years old female patient, who was already being followed for the last four years for serious aplastic anemia, since she did not respond to ATG/cyclosporine-A treatment. Epistaxis occurred in the patient on the 3rd day, by a decrease in the thrombocyte count around 10.000/mm 3 after preparatory regime, due to the blood counts which were already low due to serious aplastic anemia even before the procedure. Epistaxis, which resulted in an additional decrease in haemoglobin counts, could not be controlled by 12 units of thrombocyte suspension, tamponade and, standard procedures, continued for more than 24 hours and has led to panic in the patient. After obtaining a verbal informed consent from the patient in this critical and uncontrollable bleeding with all known medical measures, patient agreed for local 2 mL ABS is application for the severe epistaxis. Following ABS application, the bleeding has stopped in less than one minute. No side effect is observed. Although thrombocytopenia has persisted in the posttransplant period, epistaxis has not recurred in the patient. This patient is well with full-donor chimerism post-allogeneic hematopoie-tic transplantation. This is the first patient presented in English literature regarding ABS usage in haemorrhages accompanying AlloSCT.
Topical ABS application in treatment of oral bleeding infected lesions refractory to thrombocyte transfusion during aplasic period after chemotherapy in leukemia relapsed after AlloSCT
AlloSCT from a full compatible sibling was performed in a 26 years old male patient nine months ago, who was already being followed for the last two years for acute myeloid leukemia (AML-M4), since he responded to four courses of anthracyclin/Ara-C treatment. However, leukemia relapsed despite Grade II GVHD in due course and re-induction EMA chemotherapy was given leading to severe pancytopenia. Oral bleeding lesions with infected ulcers compatible with oral GVHD plus bacterial infection occurred in the patient on the 16th day following chemotherapy, by a decrease in the thrombocyte count to 3000/mm 3 . Bleeding severe mucositis which resulted in an additional decrease in cytopenias, could not be controlled by 10 units of thrombocyte suspension, antibacterial washes and, other standard procedures. After obtaining a verbal informed consent from the patient, locally 3 mL ABS was applied to the oral mucosa of the patient, since the bleeding and localized infection with Graft-versus-Host Disease (GVHD) could not be controlled with conventional methods. Following ABS application, the bleeding has instantly stopped and mucositis was healed within 2 days. No side effect is observed. Although neutropenia, anemia and thrombocytopenia has persisted in the aplasic period, mucositis has not recurred in the patient. This patient is still alive, and GVHD is now somewhat under control with steroids and immunosuppressive medications. This is the first patient presented in English literature regarding ABS usage in oral mucositis with bleeding lesions accompanying AlloSCT and chemotherapy.
Topical ABS application for the bleeding arteriovenous fistula in chronic renal failure with uremic platelet dysfunction
Seventy-year-old man with history of uremia was hospitalized for arteriovenous (AV) fistula revision. On the physical examination, moderate bleeding was observed from AV fistula. Laboratory findings revealed hemoglobine 8.2 g/dl, thrombocyte 56.000/mm 3 , D-Dimer 1341 microgram/dl. Right jugular catheter was inserted for hemodialysis. Bleeding from the jugular catheter began after insertion. Despite the use of fresh frozen plasma, platelet infusions and mechanical compression, bleeding did not stop from the AV fistulae and the catheter border. Topical ABS which is approved for external bleeding lesions in Turkey, was applied externally to the AV fistula and catheter border. Hemorrhage was stopped immediately after the ABS application without any further bleeding.
Topical ABS application for the bleeding dentalperiodontal tissue in Glansmann thrombastenia
Twenty-year-old woman with a history of Glanzmann thrombasthenia, was admitted to the hospital because of gingival bleed due to severe gingivitis. Periodontal therapy was applied. Spontaneous and periodontal therapy induced gingival bleeding was controlled with topical application of ABS. No platelet transfusion was done before and after procedure. One week later, ABS was applied to control the gingival bleeding, during the second periodontal therapy, and no platelet transfusion was required. After the effective periodontal therapy and ABS application, which is approved for dental bleeding in Turkey, to control the bleeding episodes, all the signs of severe gingivitis has disappeared and the patient recovered successfully.
Topical ABS application for the bleeding dentalperiodontal tissue in von Willebrand disease
A woman with history of type III von Willebrand disease was examined by the dental surgeon due to the severe dental pain. Extraction of left mandibular 3rd molar and premolar teeth was decided, after her examination. She had a history of severe dental bleeding, despite the administration of fresh frozen plasma in her prior teeth extraction. Both teeth were extracted without any major bleeding, after ABS application.
Topical ABS application for the bleeding dental surgery in Hemophilia-A
Fifty-five year-old man with a history of haemophilia was admitted to the hospital because of severe dental pain. Extraction of right mandibular 3rd molar teeth was decided, after his examination. His aPTT (activate partial thromboplastin time) was 67 seconds, and his factor VIII level was 1.5 %. His teeth were extracted without any major bleeding, after topical ABS application. Six days after, he had a minor dental bleeding which stopped immediately after ABS administration with no more recurrences of bleed.
Topical ABS application for the bleeding pacemaker region in thrombotic cardiac disease with warfarin-induced coagulapathy
Sixty-five years old man who was chronically anticoagulated with coumadine was admitted to the hospital, because of atrio-ventricular complete block. One week before inserting the cardiac pacemaker, coumadine was stopped. Control INR ratio value was 1.1, then the cardiac pacemaker was inserted. Immediately after the procedure, bleeding from the pacemaker was noticed. Bleeding was not controlled with the aplication of vitamin K, fresh frosen plasma and local compression. Later, after the patient verbally informed and agreed with the ABS application, then ABS was applied to the bleeding area directly. The bleeding immediately stopped. During the follow up, no more bleeding was observed. Coumadin was started again, without any further bleeding.
Topical ABS application for the bleeding groin region in thrombotic cardiac disease with abnormal fibrinolysis due to tPA administration
In a 52 years old male patient to whom coroner angiography was applied due to coroner artery disease with serious coroner artery stenosis, systemic hyperfibrinolysis formed after intra coronary tPA application followed by secondary haemostatic disturbance after heparinization and the arterial bleeding appeared in groin area could be controlled by local application of ABS.
DISCUSSION
Topical hemostatic efficacy of ABS has been previously tested in animals with normal 15, 19 and defective hemostasis. 16, 20 Numerous studies demonstrated the haemostatic effects of topical ABS application in the animals with normal 11, 13, 15, 17, 18 and defective hemostasis 16, 20 have set the preclinical stage for the development of this hemostatic product. Short-term hematological and biochemical safety of the oral systemic administration of Ankaferd to rabbits have been shown.
14 Acute mucosal toxicity, hematotoxicity, hepatotoxicity, nephrotoxicity, and biochemical toxicity were not observed during the shortterm follow-up of the animals. 14 Those preclinical results reflect a starting point to search any possible systemic confounding effect of ABS when applied to internal topical surfaces.
The usage of ABS as a hemostatic agent in external hemorrhages and in dental treatment in humans constitutes the first hints on ABS's safety and efficacy in humans. 10 A phase I double-blinded, randomized, cross-over, placebo*controlled clinical study with a 5 days' wash-out period between the cross-over periods in healthy volunteers indicated the safety of ABS. Physiological cell-based coagulation could be clinically managed via topical ABS application to prevent and treat bleeding in many distinct clinicopathological states. 11, 19, 21, 22 The experience in the transplant patient shows that ABS application can be used safely in epistaxis control with antihaemorrhagic, haemostatic effectiveness. ABS effectiveness in other bleedings observed during AlloSCT course should be investigated.
The in vitro antibacterial activity of ABS was evaluated by Akkoç et al. 23, 24 In this study, the antagonistic activity of ABS is evaluated against 26 indicator strains consisting of 26 indicator strains Gram positive and Gram negative bacteria, in human and food pathogens, using agar diffusion method, and it is demonstrated that it is effective against all strains. Nisin, a food preservative bacteriosin used as a control, is found to be inactive against Gram negative strains. In addition to its high inhibitor activity against human and food pathogens, Gram positive and Gram negative bacteriae, it is observed that ABS is more stable than nisin in various temperatures and in the presence of enzymes. 24 The antimicrobial activity of Ankaferd was tested against many pathogens. 25 The isolates included A.baumannii, E. coli, K. pneumonia, P. aeruginosa, Enterobacter spp., Stenotrophomonas maltophilia, MRSA, methicillin resistant coagulase negative Staphylococcus, vancomycin susceptible Enterococcus and VRE. They have reported that Ankaferd was active against all these isolates, with zones of inhibition which were within the 10-18 mm. diameter range. Antibacterial activities of Ankaferd against several gram positive and gram negative food and human pathogens, were also reported in another study. 24 Consequently, in addition to its haemostatic effects in haemorrhagic wounds' healing, it is pointed out that its antimicrobial property can also be beneficial, and ABS has the potential usage for preventing against various type bacterial pathogens. The experience in the relapsed leukemic transplant patient shows that ABS application can be used safely in oral mucositis controlled haemostatic and topical anti-infective effectiveness.
Exaggerated bleeding, particularly in patients with hereditary or acquired hemorrhagic diathesis, is a challenging problem in the clinic on a daily basis. Antithrombotic, procoagulant, and antifibrinolytic medications are frequently used for the management of bleeding. Ankaferd-induced formation of the protein network covers the entire physiological hemostatic process without unequally affecting any individual clotting factor in many pathobiological states.
1-3,5-31 ABS may, therefore, be effective both in individuals with normal haemostatic parameters and in patients with deficient primary haemostasis and/or secondary haemostasis. After the approval of Ankaferd for the management of dental bleeding by Turkish Ministry of Health, ABS has been added to the protocols of prevention and treatment of exaggerated hemorrhage due to dental procedures in Turkey. In this study, controlling clinical critical bleeding states associated with deficiencies of either primary or secondary hemostasis have been examined retrospectively. The patients with bleeding diathesis about controlling critical bleedings that could not be controlled with standard anti-haemorrhagic methods, with topical ABS are herein presented. The observations in these patients are promising regarding the usage of ABS in anticoagulated patients and hereditary bleeding disorders such as clotting factor deficiencies. Future controlled trials shall be performed to fully elucidate the efficacy of ABS in those difficult clinical settings with hemorrhagic diathesis.
